FOLH1 and Familial prostate cancer: It is important to mention that the 177Lu2O3-iPSMA nanoparticles developed in this research are not proposed as an option to replace prostate cancer therapies using ligands targeting PSMA, such as 177Lu-PSMA-617 or 177Lu-iPSMA [31,32]; what is proposed is the possibility of using 177Lu2O3-iPSMA for the treatment of liver metastases or tumors that express PSMA in the neovasculature, even with reduced or null expression of PSMA on the membrane of cancer cells.